Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
Official title: A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Dose Regimens of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
617
Start Date
2026-10
Completion Date
2029-03
Last Updated
2026-10-20
Healthy Volunteers
No
Interventions
LY4167586
administered SC
Placebo
administered SC
Locations (12)
CenExel ACT
Anaheim, California, United States
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Advanced Pharma CR, LLC
Miami, Florida, United States
Clinical Site Partners, LLC DBA CSP Orlando
Winter Park, Florida, United States
CenExel iResearch, LLC
Decatur, Georgia, United States
CenExel-HRI
Marlton, New Jersey, United States
Ohio Clinical Trials
Columbus, Ohio, United States
Fortrea Clinical Research Unit
Dallas, Texas, United States
Worldwide Clinical Trials, Inc.
San Antonio, Texas, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore